Sanofi Return on Investment 2012-2026 | SNY
Current and historical return on investment (ROI) values for Sanofi (SNY) over the last 10 years.
| Sanofi ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-03-31 | $9.83B | $97.91B | 10.04% |
| 2025-12-31 | $9.83B | $95.61B | 10.28% |
| 2025-09-30 | $9.76B | $95.55B | 10.21% |
| 2025-06-30 | $9.64B | $70.64B | 13.65% |
| 2025-03-31 | $9.13B | $69.97B | 13.05% |
| 2024-12-31 | $8.22B | $47.27B | 17.39% |
| 2024-09-30 | $8.54B | $47.02B | 18.17% |
| 2024-06-30 | $7.84B | $47.02B | 16.67% |
| 2024-03-31 | $8.45B | $47.77B | 17.69% |
| 2023-12-31 | $9.59B | $47.77B | 20.08% |
| 2023-09-30 | $10.30B | $47.48B | 21.70% |
| 2023-06-30 | $11.11B | $47.48B | 23.40% |
| 2023-03-31 | $10.71B | $46.92B | 22.82% |
| 2022-12-31 | $10.72B | $46.92B | 22.85% |
| 2022-09-30 | $12.21B | $23.21B | 52.62% |
| 2022-03-31 | $8.80B | $24.49B | 35.93% |
| 2021-09-30 | $9.03B | $24.49B | 36.89% |
| 2021-03-31 | $10.31B | 0 | 0.00% |
| 2020-09-30 | $9.32B | 0 | 0.00% |
| 2020-03-31 | $7.94B | 0 | 0.00% |
| 2019-09-30 | $6.79B | $20.51B | 33.11% |
| 2019-03-31 | $6.71B | $20.51B | 32.71% |
| 2018-03-31 | $6.77B | $40.58B | 16.67% |
| 2017-12-31 | $7.07B | $40.58B | 17.42% |
| 2017-09-30 | $7.72B | $40.69B | 18.98% |
| 2017-06-30 | $8.01B | $40.69B | 19.69% |
| 2017-03-31 | $8.14B | $40.16B | 20.27% |
| 2016-12-31 | $7.59B | $40.16B | 18.91% |
| 2016-09-30 | $8.06B | $19.54B | 41.24% |
| 2016-06-30 | $7.47B | $38.22B | 19.54% |
| 2016-03-31 | $7.72B | $39.90B | 19.35% |
| 2015-09-30 | $7.96B | $61.74B | 12.90% |
| 2015-06-30 | $7.84B | $83.14B | 9.42% |
| 2014-06-30 | $8.29B | $64.46B | 12.86% |
| 2013-06-30 | $8.36B | $67.23B | 12.43% |
| 2012-06-30 | $9.00B | $45.39B | 19.82% |
| 2012-03-31 | $8.41B | $47.69B | 17.63% |
| 2011-12-31 | $8.89B | $47.69B | 18.64% |
| 2011-09-30 | $8.20B | $43.61B | 18.80% |
| 2011-06-30 | $8.97B | $43.61B | 20.57% |
| 2011-03-31 | $10.32B | $38.94B | 26.49% |
| 2010-12-31 | $9.22B | $38.94B | 23.67% |
| 2010-09-30 | $8.91B | $37.99B | 23.46% |
| 2010-06-30 | $8.83B | $37.99B | 23.25% |
| 2010-03-31 | $8.80B | $36.60B | 24.05% |
| 2009-12-31 | $8.81B | $36.60B | 24.08% |
| 2009-09-30 | $9.40B | $35.74B | 26.30% |
| 2009-06-30 | $8.62B | $35.74B | 24.12% |
| 2009-03-31 | $7.71B | $35.99B | 21.42% |
| 2008-12-31 | $7.99B | $35.99B | 22.20% |
| 2008-09-30 | $7.86B | $34.48B | 22.79% |
| 2008-06-30 | $8.22B | $34.48B | 23.83% |
| 2008-03-31 | $7.78B | $33.56B | 23.19% |
| 2007-12-31 | $7.93B | $33.56B | 23.62% |
| 2007-09-30 | $7.81B | $32.76B | 23.85% |
| 2007-06-30 | $7.00B | $32.76B | 21.36% |
| 2007-03-31 | $6.85B | $31.15B | 22.01% |
| 2006-12-31 | $5.85B | $31.15B | 18.78% |
| 2006-09-30 | $3.94B | $31.40B | 12.55% |
| 2006-06-30 | $5.16B | $31.40B | 16.43% |
| 2006-03-31 | $4.82B | $32.37B | 14.89% |
| 2005-12-31 | $4.48B | $32.37B | 13.85% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |